Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)

Summary Background Chronic rhinosinusitis with nasal polyps (CRSwNP), an inflammatory disease of the paranasal mucosa, is primarily characterized by type 2 inflammation. Three antibodies (dupilumab, omalizumab, and mepolizumab) are now approved for treatment severe CRSwNP. Documentation severity during course essential. Methods A literature search Medline, PubMed, national international trial guideline register, Cochrane Library was performed to analyze immunology CRSwNP determine evidence effect dupilumab, mepolizumab in this disease. This has resulted 3 position papers prepared our group authors, which form basis summarizing review. Results Based on information from literature, recommendations use German health care system given expert panel. Conclusion Dupilumab, patients 18 years age older as add-on therapy intranasal corticosteroids when, dupilumab mepolizumab, systemic and/or surgery does not achieve sufficient control. Therapy omalizumab indicated when result Dedicated documentation given, based author already published topic.